Roche Steps Closer To Flu Market Domination With Phase III Baloxavir Results
Executive Summary
Not even a month after the FDA granted the antiviral Priority Review, baloxavir marboxil has shown superior efficacy in its primary endpoint in the latest CAPSTONE-2 Phase III clinical study, taking it closer to possible market supremacy for influenza A and B.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer
Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Roche Pushes Personalization With $2.4bn Foundation Buy-Out
By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.